

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2782897

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOSTRATUM AB	07/04/2007
RECEIVING PARTY DATA	
Name:	BIOCRINE AB
Street Address:	JOHN ERIKSSONSGATAN 9
City:	STOCKHOLM
State/Country:	SWEDEN
Postal Code:	112 22
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14222058
CORRESPONDENCE DATA	
Fax Number:	(312)913-0002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-913-0001
Email:	harper@mbhb.com
Correspondent Name:	MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
Address Line 1:	300 SOUTH WACKER DRIVE
Address Line 2:	SUITE #3100
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	03-390-USDIV4CO
NAME OF SUBMITTER:	DAVID HARPER
SIGNATURE:	/David Harper/
DATE SIGNED:	03/25/2014
Total Attachments: 6	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page1.tif	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page2.tif	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page3.tif	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page4.tif	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page5.tif	
source=03-390 Assignment (BioStratum AB to BioCrine AB)#page6.tif	

PATENT



PATENT APPLICATION ASSIGNMENT

WHEREAS, BioStratum, AB ("ASSIGNOR"), a Swedish corporation, having its principal office at Sandhamnsgatan 23, 115 28 Stockholm, Sweden, owns the patent applications listed in Table 1 (PATENT APPLICATIONS); and

WHEREAS, BioCrine AB ("ASSIGNEE"), a Swedish corporation, having its principal office at John Erikssonsgatan 9, 112 22 Stockholm, Sweden desires to acquire the entire right, title and interest in the PATENT APPLICATIONS;

WHEREASE ASSIGNOR and ASSIGNEE have entered into an Asset Transfer Agreement dated June 8, 2007, in which it was agreed that the PATENT APPLICATIONS would be assigned to ASSIGNEE

NOW THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the PATENT APPLICATIONS, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other patent applications claiming the benefit of the filing date of the PATENT APPLICATIONS, to ASSIGNEE, its successors and assigns. For said consideration, ASSIGNOR hereby agrees, upon the request and at the expense of ASSIGNEE, its successors and assigns, to execute any and all applications claiming priority to the above-referenced application, and all divisional, continuation and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application and any and all applications and other documents for Letters Patent in foreign countries on said invention or improvements, that said assignee, its successors or assigns may deem necessary or expedient, and for the said considerations ASSIGNOR authorize ASSIGNEE to apply for patents for said invention or improvements in its own name in such countries where such procedure is proper and further agree, upon the request of ASSIGNEE, its successors and assigns, to cooperate to the best of the ability of ASSIGNOR with ASSIGNEE, its successors and assigns, in any proceedings or transactions involving the PATENT APPLICATIONS, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain, maintain and enforce said Letters Patent, both United States and foreign, and vest all rights therein hereby conveyed in the ASSIGNEE, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the ASSIGNEE, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment had not been made.

ASSIGNOR hereby authorizes and requests the respective Commissioner of Patents and Trademarks to issue any Letters Patent which may issue for the PATENT

9

APPLICATIONS, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby warrants itself to be the owner of the entire right, title and interest in said PATENT APPLICATIONS and to have the right to make this assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent that may issue from the PATENT APPLICATIONS.

BioStratum AB

Date: July 4, 2007

Signature: 


Printed Name: EUGEN STEINER

Title: CHAIRMAN

I, the undersigned ELAINE CIGÉHN, a Deputy Notary Public of the city of Stockholm, Sweden, do hereby certify that Mr Eugen Steiner who has/have personally signed this document on behalf of BioStratum AB is/are duly qualified to sign for the said company on July 4, 2007. was Stockholm, February 28, 2008

Ex officio:


Notary Public



APOSTILLE
(Convention de La Haye du 5 octobre 1961)


1. Country: Sweden
This public document
2. has been signed by Elaine Cigéhn
3. acting in the capacity of Deputy Notary Public
4. bears the seal/stamp of Deputy Notary Public
Elaine Cigéhn Stockholm

Certified

5. at Stockholm 6. the 26th of Febr., 2008
7. by Mikael Bratt
Notary Public
8. N° 726/08
9. Seal/stamp: 10. Signature:



TABLE 1: PATENT APPLICATIONS




MBHB Case No.	Serial No/Patent No./Filing Date/Issue Date	Inventor(s)	Title
04-227-USCO (Continuation)	11/510,232 Filed: August 25, 2006	Suad Efendic	Methods for Identifying Compounds for Treating Diabetes Mellitus
02-1220 (Utility)	10/108,953 Filed: March 28, 2002	Per-Olof Berggren Barbara Leibiger Ingo Leibiger	Novel Mechanism for Identifying Drugs for the Treatment of Type II Diabetes
02-1220-CO (Continuation)	11/492,530 Filed: July 25, 2006	Per-Olof Berggren Barbara Leibiger Ingo Leibiger	Novel Mechanism for Identifying Drugs for the Treatment of Type II Diabetes
02-193-US (Utility)	10/392,810 Filed: March 19, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 subunit of L-Type Ca ²⁺ Channels
02-193-USCO (Continuation)	11/510,105 Filed: August 25, 2006	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca ²⁺ Channels
02-193-PCT (PCT)	PCT/EP03/02929 Filed: March 20, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca ²⁺ Channels
02-193-AU (Australia)	2003216860 Filed: March 20, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca ²⁺ Channels
02-193-CA (Canada)	2,479,414 Filed: March 20, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca ²⁺ Channels
02-193-EP (Europe)	03712063.1 Filed: March 20, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca ²⁺ Channels
02-193-JP (Japan)	2003576624 Filed: March 20,	Per-Olof Berggren and	Inhibition of the Beta3 Subunit of L-Type

9

	2003	Veit Flockerzi	Ca2+ Channels
02-193-MX (Mexico)	2004-009105 Filed: March 20, 2003	Per-Olof Berggren and Veit Flockerzi	Inhibition of the Beta3 Subunit of L-Type Ca2+ Channels
04-631-PCT (PCT)	PCT/EP05/009238 Filed: August 26, 2005	Per-Olof Berggren and Lisa Juntti Berggren	Methods and compounds for treating diabetes
04-631-EP (Europe)	05791454.1 Filed: August 26, 2005	Per-Olof Berggren and Lisa Juntti Berggren	Methods and compounds for treating diabetes
03-390-US (Utility)	10/834,525 Filed: April 29, 2004	Per-Olof Berggren	ApoCIII and the Treatment and Diagnosis of Diabetes
03-390-PCT (PCT)	PCT/US04/13529 Filed: April 29, 2004	Per-Olof Berggren	ApoCIII and the Treatment and Diagnosis of Diabetes
03-390-EP (Europe)	04751089.6 Filed: April 29, 2004	Per-Olof Berggren	ApoCIII and the Treatment and Diagnosis of Diabetes

3



McDONNELL BOEHNEN HULBERT &
BERGHOFF LLP
300 South Wacker Drive
32nd Floor
CHICAGO IL 60606-6709
USA

Invoice No	4119140	Page	1
Client	144891SC	Invoice date	2008-02-27
		Due Date	2008-03-28
Our reference			
810627000/ZSE/ANN			

Your reference

Legalization of Assignment document
Mexican Patent Application No. 4004-009105

The services were performed from 22/02/2008 to 27/02/2008

(1474/19)

Specification

Amount SEK

Legalisation of Assignment
Mexican Patent Application No. 4004-009105

1 460,00

Net Taxable	Net Non Taxable	VAT Amount	VAT Percent	Total Amount SEK
1 460,00	0,00	0,00	25%	1 460,00

Our VAT No SE556000217101 **Client VAT No.** **EAN No.**

EU-clients only: 0% VAT reverse charge

Payment terms: 30 days net.

Please quote the client and invoice number with your payment.

Zacco Sweden AB
P O Box 23101
Visitors address: Sveavägen 151
SE-104 35 Stockholm Sweden

Tel +46 8 729 95 00
Fax +46 8 31 83 15
e-mail info@zacco.se
www.zacco.se

Nordea Bank Sweden
Swift: NDEASESS Acc.no 4051 1325114
IBAN No: SE1730000000040511325114
Bankgiro no.: 562-9779
European patent and trademark attorneys